Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Phase 3

Not yet recruiting

Conditions: Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Hormone Sensitive Prostate Cancer
Prostate Cancer
Cancer of the Prostate

Interventions: Drug: Mevrometostat
Drug: Placebo
Drug: Enzalutamide

First Posted Date: 2025-06-19

Last Posted Date: 2025-07-02

Lead Sponsor: Pfizer

Target Recruit Count: 1000

Registration Number: NCT07028853

Locations: 🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
🇺🇸
Arizona Urology Specialists, PLLC, Tucson, Arizona, United States
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

and more 7 locations

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

Phase 3

Not yet recruiting

Conditions: Severe Alopecia Areata

Interventions: Drug: Ritlecitinib higher dose
Drug: Ritlecitinib lower dose

First Posted Date: 2025-06-19

Last Posted Date: 2025-06-19

Lead Sponsor: Pfizer

Target Recruit Count: 140

Registration Number: NCT07029828

A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

Phase 3

Not yet recruiting

Conditions: Severe Alopecia Areata

Interventions: Drug: Ritlecitinib higher dose
Drug: Ritlecitinib lower dose
Drug: Placebo

First Posted Date: 2025-06-19

Last Posted Date: 2025-06-19

Lead Sponsor: Pfizer

Target Recruit Count: 225

Registration Number: NCT07029711

A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant

Phase 1

Not yet recruiting

Conditions: Pneumococcal Disease

Interventions: Biological: 20vPnC

First Posted Date: 2025-06-15

Last Posted Date: 2025-06-15

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT07023081

Locations: 🇨🇳
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, Guangxi, China
🇨🇳
Wuming District Center for Disease Control and Prevention, Chengxiang, Nanning, China

A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults

Phase 1

Not yet recruiting

Conditions: Pneumococcal Disease

Interventions: Biological: 20vPnC
Biological: 13vPnC

First Posted Date: 2025-06-13

Last Posted Date: 2025-07-01

Lead Sponsor: Pfizer

Target Recruit Count: 400

Registration Number: NCT07019909

Locations: 🇨🇳
Zhejiang provincial center for disease control and prevention, Hangzhou, Zhejiang, China
🇨🇳
Kaihua County Center For Disease Prevention and Control, Kaihua, Zhejiang, China

A Study to Understand How the Study Medicine (PF-07976016) is Processed and Eliminated in Healthy Men

Phase 1

Recruiting

Conditions: Healthy Male Volunteers

Interventions: Drug: [14C] PF-07976016
Drug: PF-07976016

First Posted Date: 2025-06-11

Last Posted Date: 2025-06-22

Lead Sponsor: Pfizer

Target Recruit Count: 8

Registration Number: NCT07015918

Locations: 🇳🇱
ICON, Groningen, Netherlands

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

Phase 3

Not yet recruiting

Conditions: COVID-19 Infection

Interventions: Drug: ibuzatrelvir
Drug: placebo for remdesivir
Drug: remdesivir
Drug: placebo for ibuzatrelvir

First Posted Date: 2025-06-10

Last Posted Date: 2025-06-24

Lead Sponsor: Pfizer

Target Recruit Count: 300

Registration Number: NCT07013474

Locations: 🇺🇸
Hope Clinical Research, Inc., Canoga Park, California, United States
🇯🇵
Rinku General Medical Center, Izumisano, Osaka, Japan
🇯🇵
National Center for Global Health and Medicine, Shinjuku City, Tokyo, Japan

and more 9 locations

A Study to Learn How the Study Medicine Called [14C]PF-07054894 is Processed by the Body

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: PF-07054894

First Posted Date: 2025-06-06

Last Posted Date: 2025-06-29

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT07009353

Locations: 🇳🇱
ICON, Groningen, Netherlands

A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults

Phase 1

Not yet recruiting

Conditions: Healthy

Interventions: Drug: PF-07985631
Drug: Placebo

First Posted Date: 2025-05-29

Last Posted Date: 2025-06-25

Lead Sponsor: Pfizer

Target Recruit Count: 92

Registration Number: NCT06994897

A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine

Phase 1

Recruiting

Conditions: Acute Treatment of Migraine

Interventions: Drug: Zavegepant

First Posted Date: 2025-05-29

Last Posted Date: 2025-07-02

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT06995729

Locations: 🇺🇸
Clinical Research Institute, Minneapolis, Minnesota, United States
🇺🇸
Accellacare - Piedmont, Statesville, North Carolina, United States
🇺🇸
Accellacare of Piedmont HealthCare, Statesville, North Carolina, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy